Physician profile
Nesreen Kurtom
NPI 1093861072
$8,936.89
in general payments reported to CMS, 2019-2025
37 companies · $2,676 in 2025
The $2,676 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9.20 · 2021: $20.50 · 2022: $620 · 2023: $1,426 · 2024: $4,186 · 2025: $2,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,047 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,047.06 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,673.00 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,665.41 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,142.02 | 2023-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $616.21 | 2023-2025 | |
| Lilly USA, LLC | $367.98 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.84 | 2023-2024 | Jardiance |
| Abbott Laboratories | $251.60 | 2024-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $243.33 | 2024-2025 | Spravato |
| Abbvie INC. | $238.69 | 2024-2025 | |
| Shield Therapeutics INC | $229.61 | 2024-2025 | |
| Astellas Pharma US INC | $227.09 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $209.77 | 2025 | |
| Dexcom, INC. | $143.43 | 2024-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $143.12 | 2024-2025 | Eliquis, Camzyos |
| Corcept Therapeutics | $141.48 | 2024-2025 | Korlym |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nesreen Kurtom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.